Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHDSYF)

• Drug Name: CRX-675 Drug Info
• Synonyms: RC-529

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis virus infection	1E50-1E51	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMHDSYF

Molecule-Related Drug Atlas

Drug(s) Targeting Toll-like receptor 4 (TLR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MPL-containing Pollinex allergy desensitization vaccine	DMXSDJU	Allergy	4A80-4A85	Preregistration	[3]
Cadi-05	DMPTCYB	Prostate cancer	2C82.0	Phase 3	[4]
Resatorvid	DMFMWYC	Sepsis	1G40-1G41	Phase 3	[5]
ERITORAN	DMKQZ0L	Sepsis	1G40-1G41	Phase 3	[6]
G100	DMKHNXA	Non-hodgkin lymphoma	2B33.5	Phase 2	[7]
OM-174	DM2THBX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
NI-0101	DM31FOP	Autoimmune diabetes	5A10	Phase 1	[2]
GSK1795091	DMC6QE4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
CS-4771	DMVDLT4	Sepsis	1G40-1G41	Discontinued in Phase 1	[9]
LZ-8	DM679IY	Autoimmune diabetes	5A10	Terminated	[2]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 4 (TLR4)	TTISGCA	TLR4_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT00076037) Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP. U.S. National Institutes of Health.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
• [3] Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006.
• [4] Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
• [5] Clinical pipeline report, company report or official report of Takeda (2009).
• [6] Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
• [9] Eritoran insight for influenza treatment. SciBX 6(19); doi:10.1038/scibx.2013.453. May 16 2013